Following non-submission
AWMSG advice |
||
| Status: Not endorsed (Statement of Advice) | ||
In the absence of a submission from the holder of the marketing authorisation, dexamfetamine sulfate cannot be endorsed for use within NHS Wales for the treatment of narcolepsy and children with refractory hyperkinetic states under the supervision of a physician specialising in child psychiatry. |
||
|
||
Medicine details |
||
| Medicine name | dexamfetamine sulfate | |
| Formulation | 1 mg/ml oral solution | |
| Reference number | 2342 | |
| Indication | Treatment of narcolepsy and children with refractory hyperkinetic states under the supervision of a physician specialising in child psychiatry |
|
| Company | Martindale Pharma | |
| BNF chapter | Central nervous system | |
| Assessment type | Non-submission | |
| Status | Not endorsed (Statement of Advice) | |
| Date of issue | 26/02/2014 | |